Pentoxifylline Injection (Aoting) 0.1g/5ml × 6 Vials
1 × $2.00 
Compound L?Aspartate L?Ornithine Granules 3?g (Rigan) – Wholesale & Research Use
1 × $1.00 Subtotal: $3.00
$1.00
Lparomlimab & Tuvonralimab Injection Qibeian is a bi-functional monoclonal antibody combination (PD?1/CTLA?4) developed by Qilu Pharmaceutical (QL1706), supplied as 50?mg in 2?mL vials. Approved by China’s NMPA (conditional marketing authorization No. S20240044; drug code 86904021005238). Intended exclusively for lab and investigative research applications, not for clinical or human use.
| Attribute | Information |
|---|---|
| Product Name | Lparomlimab & Tuvonralimab Injection (Qibeian® / QL1706) |
| Formulation | Injection, 50?mg in 2?mL vial |
| Approval No. | China NMPA S20240044 |
| Drug Standard Code | 86904021005238 |
| Manufacturer | Qilu Pharmaceutical Co., Ltd. |
| Intended Use | For research use only, not for therapeutic use |
Qibeian (QL1706) combines two antibodies—lparomlimab (anti-PD?1) and tuvonralimab (anti-CTLA?4)—in a single product. This dual blockade enhances T-cell activation through simultaneous PD?1/CTLA?4 pathway inhibition
Conditionally approved by NMPA in September 2024 for recurrent/metastatic cervical cancer post-platinum therapy
Phase II (DUBHE?C?206): In recurrent/metastatic cervical cancer, objective response rate (ORR): 33.8%, disease control rate (DCR): 64.9%, median PFS: 5.4 months (148 patients)
Safety: 70.3% experienced treatment?related adverse events; 24.3% had grade ?3 TRAEs—most commonly anemia, thyroid dysfunction, GGT elevation
Ideal for preclinical and translational studies on:
Immune checkpoint inhibition
Tumor microenvironment research
Combination studies (e.g., with chemotherapy, targeted agents, radiotherapy)
Biomarker and pharmacodynamic assays
Storage: 2?–?8?°C, avoid freezing.
Handling: Use aseptic technique in a biosafety cabinet.
Stability: Per manufacturer instructions (CCF refrigerated vials).
NMPA conditional approval announcement pubmed.ncbi.nlm.nih.gov+4english.nmpa.gov.cn+4english.nmpa.gov.cn+4
First approval review in Drugs journal biospace.com+15pubmed.ncbi.nlm.nih.gov+15bydrug.pharmcube.com+15
DUBHE?C?206 Phase II trial data delta.larvol.com+4biospace.com+4sohu.com+4
Preclinical combination studies bydrug.pharmcube.com+5biospace.com+5prnewswire.com+5
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 18 × 16 厘米 |
Propranolol Hydrochloride Oral Solution (HeMeiJia) offers a sweet strawberry-mint 40?mg/5?mL formulation in a 40?mL bottle. Approved by NMPA under H20213549, this solution provides accurate dosing—ideal for infantile hemangioma, pediatric cardiovascular, or pharmacokinetic studies.
?? For laboratory research or analytical purposes only – Not for therapeutic use.
Select at least 2 products
to compare
评价
目前还没有评价